看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
2 Z* L- O3 G) T; C2 @" E" Z9 ~, ?* m( T
: f$ [8 w0 C+ j: ^# R y+ ?Currently available feasibility data for possible combination strategies. ; Z# H9 a( `. b# r4 }5 f! ~9 z
————————————————————————————————0 U7 E# T- L: b* Z' X% y
Combination Feasibility according to preliminary data 7 R5 \3 y) L5 ^4 L
——————————————————————————————————% y& Q, H0 N0 {; U. d8 B x
Bevacizumab + sorafenib Yes, reduced dose
9 g/ ~9 V! k, M6 \8 O. ?( M/ NBevacizumab + sunitinib† No " w2 n* l7 y, a0 b; V4 L" M
Bevacizumab + temsirolimus Yes % w8 r$ H$ R. _1 E' O: A" s
Bevacizumab + everolimus Yes 8 c9 x) e1 a: u+ _( H
Sorafenib + sunitinib ? 2 P: O6 A) m4 G6 v
Sorafenib + temsirolimus Yes, reduced dose : l: l; z0 x8 O2 Z: a( l9 m
Sorafenib + everolimus Yes, reduced dose
: @1 ^4 M) C# E' _+ VSunitinib + temsirolimus† No
3 E6 Z" P: j7 u' b7 ESunitinib + everolimus ?
% {% o" [* ]( W+ ~+ T( h2 A$ C! TTemsirolimus + everolimus ?
. \4 j2 Q% ?* D. |# |————————————————————( g. g4 P P. |. f
†Led to US FDA warning., m! j: L g* P& V6 P6 p+ {
?: As yet unattempted combination.
5 V( R: x, h7 E5 O, ^: T' Z# u |